Benchmark analyst Matthew Harrigan raised the firm’s price target on Live Nation (LYV) to $190 from $180 and keeps a Buy rating on the shares, but notes that the firm is “more significantly deferring realization into 2026” for its increased target given the “Washington regulatory cloud” that persists with further FTC action this month via a lawsuit. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

价格目标调整 - Raymond James将Range Resources目标价从45美元下调至41美元 但维持优于大盘评级 [1] - 公司认为若强劲天然气前景在未来几年实现 该股存在更大上行潜力 [1] 投资前景 - 分析师通过研究报告向投资者传达对天然气行业的积极展望 [1] - 天然气行业未来几年可能呈现强劲发展态势 [1]

Lake Street analyst Ben Klieve lowered the firm’s price target on Bioceres (BIOX) to $5 from $8 and keeps a Buy rating on the shares. Q4 results were materially below all estimates in each segment, though the firm believes FY25 will prove to be an EBITDA trough and sees value in the next-generation products throughout Bioceres’ portfolio, the analyst tells investors in a post-earnings note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, a ...

价格目标调整 - Evercore ISI将Americold Realty Trust目标价从22美元下调至19美元 [1] - 公司维持对该股的跑赢大盘评级 [1] 模型调整原因 - 调整基于近期REIT会议后的多项模型更新 [1] - 调整反映了公司会议获得的洞察及更广泛的市场状况 [1]

Evercore ISI analyst Steve Sakwa raised the firm’s price target on Rexford Industrial (REXR) to $39 from $38 and keeps an In Line rating on the shares. The firm made several model adjustments following a recent REIT conference, reflecting insights from company meetings and broader market conditions. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published fir ...

公司股价表现 - 股价下跌1.5%至103.83美元 但100美元支撑位仍低于当前水平[1] - 年内累计下跌23.3% 处于稳步上升通道内整理[1] - 过去三次财报发布后股价均下跌 包括11月21.4%的大幅下跌[4] 财报预期 - 8月20日盘前发布第二季度财报[4] - 预期盈利和收入均同比下降[4] - 期权市场定价预期股价双向波动10.9%[4] 机构评级 - Edgewater Research将评级从"中性"下调至"表现不佳"[5] - Truist维持"持有"评级但将目标价上调至17美元[5] - 覆盖机构中19家给予"持有"评级 12家"买入" 3家"强烈卖出"[5][6] - 12个月共识目标价105.68美元 较现价仅溢价1.8%[6] 期权市场动向 - 看跌期权活跃度异常 50日看跌/看涨成交量比率达0.94[7] - 该比率高于过去一年90%的读数水平[7] - 绝对量上看涨期权仍占优势但看跌期权需求增长显著[7] 业务动态 - 2026年终止与Ulta Beauty的店中店合作计划[1]

管理层变动 - 首席执行官Andrew Witty因个人原因辞职 由2006至2017年期间担任过该职位的Stephen Hemsley接任[1] - Hemsley将继续担任董事会主席 Witty将转任首席执行官高级顾问[1] 财务表现 - 调整后每股收益为7.20美元 高于去年同期的6.91美元 但低于市场预期的7.29美元[3] - 收入同比增长6.8%至1096亿美元 低于市场预期的1116亿美元[3] - 公告后股价上涨2.7%至319.78美元[3] 业务展望 - 暂停2025年业绩指引 因护理活动持续加速[1] - 医疗保险优势计划新参保人的医疗成本高于预期 福利 offerings范围较第一季度扩大[2] - 预计2026年恢复增长[2] 分析师观点 - Keybanc维持超配评级 目标价从575美元下调至450美元[7] - Baird维持跑赢大盘评级 目标价从510美元下调至356美元[7]